Modern wireless communication systems prefer higher frequencies to meet the growing demand for faster data transfer. The ...

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to ...

Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...

Two-dimensional (2D) perovskites are increasingly recognized as promising candidate materials for the next generation of ...

Herpes is one of the most common sexually transmitted infections, yet it's surrounded by confusion and misinformation. Many ...

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patie ...

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of ...

Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has ...

"With a Phase 2a asset in HSV and an EBV program approaching clinical readiness, Innovative Molecules is uniquely positioned as a leading developer of next-generation therapies targeting herpesviruses ...